OrthoPediatrics surpassed 500 procedures performed globally with ApiFix® technology for the treatment of progressive adolescent idiopathic scoliosis (AIS). Long-term clinical follow-up with the system now exceeds nine years.
ApiFix's Internal Brace Option™ presents an alternative for treating progressive moderate scoliosis in adolescents.
OrthoPediatrics has recruited 20 U.S. clinical centers to enter data related to the use of the ApiFix system into a post-approval study registry. The ApiFix MID-C System has obtained FDA and CE Mark approvals.
ApiFix was acquired by OrthoPediatrics in 2020, and operates as a wholly-owned subsidiary based in Israel.